Heart health unexpectedly affected by shingles vaccine

The shingles vaccine has long been known for its ability to protect against the painful viral infection and rash that can result from the varicella zoster virus. However, recent studies have suggested that the benefits of the vaccine may extend beyond just preventing shingles.

One such study, conducted in South Korea, found that individuals who received the shingles vaccine had a 23% lower risk of developing heart issues such as stroke, heart failure, and coronary artery disease. The study, which analyzed data from over 1.2 million people aged 50 or older, also found that the vaccine’s heart health benefits were more pronounced in individuals under 60 years old.

Lead author Professor Dong Keon Yon from the Kyung Hee University College of Medicine in Seoul, South Korea, explained that the primary symptom of shingles, a painful rash, can lead to serious complications, particularly in older adults and those with weakened immune systems. Without vaccination, about 30% of people may develop shingles in their lifetime.

Yon noted that shingles has been linked to a higher risk of heart problems, which prompted the researchers to investigate whether the vaccine could lower this risk. The study’s findings suggest that the shingles vaccine may indeed help reduce the risk of heart disease, even in individuals without known risk factors.

The researchers proposed several potential reasons for the vaccine’s protective effect on heart health. They suggested that a shingles infection can cause blood vessel damage, inflammation, and clot formation that can lead to heart disease. By preventing shingles, vaccination may lower these risks.

However, Dr. Jasdeep Dalawari, an interventional cardiologist, cautioned that the study used a live vaccine, while the U.S. uses a recombinant vaccine called Shingrix, which is over 90% effective against shingles. Dalawari emphasized that the study shows correlation, not causation, and further research is needed to confirm the findings.

Despite the study’s limitations, including a homogenous participant pool and the absence of a direct causal relationship, the researchers are hopeful that their findings will prompt further investigation into the heart health benefits of the shingles vaccine. As they continue their research, they aim to explore the potential benefits of the non-live, recombinant vaccine in diverse populations.

For more information on health-related topics, visit www.foxnews.com/health. Melissa Rudy, senior health editor at Fox News Digital, can be reached at melissa.rudy@fox.com for story tips and inquiries.